Estimation of the in vivo neutralization potency of eCD4Ig and conditions for AAV-mediated production for SHIV long-term remission

Author:

Goyal Ashish1ORCID,Gardner Matthew2ORCID,Mayer Bryan T.1ORCID,Jerome Keith R.13ORCID,Farzan Michael4ORCID,Schiffer Joshua T.156ORCID,Cardozo-Ojeda E. Fabian1ORCID

Affiliation:

1. Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

2. Department of Medicine, Emory University, Atlanta, GA, USA.

3. Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.

4. Department of Immunology and Microbiology, Scripps Research Institute, Florida Campus, Jupiter, FL, USA.

5. Department of Medicine, University of Washington, Seattle, WA, USA.

6. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Abstract

eCD4Ig has an in vivo IC 50 of 25 μg/ml, and it may induce ART-free virus control if produced continually at 10 5 μg/day or more.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3